ASCO 2020：11项中华人民共和国研究入选口头报告，17项Poster报告

受全球另行冠疫情直接影响，原定于5月29日~6月2日在芝加哥开幕的英国药理学学不会（ASCO）年不会来年将首次以线上形式举办，这是目前最大规模的线上盛不会。今天，全体不会议的简介题目出炉，共103个sessions，里面国共约11项研究者入选口头报告，17项入选Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

萘替尼或拉帕替尼加卡培他埠头常用HER2+前列腺癌乳腺胰脏（PHOEBE）：一项III期随机检验。

三场：前列腺癌乳腺胰脏

原作者：里面国医学科学院的医院徐兵河研究者员、马飞研究者员，复旦大学附属的医院胡夕春研究者员等

简介号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可手术后三阴性乳腺胰脏标准疗程后卡培他埠头保有节拍治疗的III期检验（SYSUCC-001）。

三场：乳腺胰脏—全局/周围/常规疗程

原作者：里面山大学禁毒里面心王树森研究者员等

简介号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

借助前列腺癌脑的环境因素特性来预报静脉里面循环DNA检查的概率: 另行辅助工具抗衡老对手

三场：另行辅助工具解决老问题

原作者：李美芹 李戈尔韦等

简介号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

多纳非尼对马利拉非尼作为更早肝蛋白胰脏的前沿疗程：一项新开表单、随机、多里面心II/III期检验。

三场：腹腔肠道胰脏—腹腔膀胱、肾上腺和实无

原作者：东南大学伊万基夫齐的医院毕锋研究者员、里面国民主自由解放军上海浦东的医院秦叔逵研究者员等

简介号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

里面国更早肝胰脏病患者阿帕替尼一线疗程：一项随机、安慰剂依此、结果表明III期研究者

三场：腹腔肠道胰脏—腹腔膀胱、肾上腺和实无

原作者：里面国民主自由解放军上海浦东的医院秦叔逵研究者员、东南大学伊万基夫齐的医院李秋研究者员等

简介号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

更早病情恶化性卵巢胰脏二次蛋白减灭术的一项随机III期检验：SOC1 / SGOG-OV2。

回顾：妇产科胰脏症

原作者：复旦大学附属里面山的医院臧荣余研究者员等

简介：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈胰脏根治性卵巢切除术后常规疗程里面的序贯放治疗对比分开放疗或该系统放治疗（STARS研究者）：一项随机、依此、新开表单的III期检验。

全体不会议：妇产科胰脏症

原作者：里面山大学禁毒里面心黄鹤研究者员、刘继红研究者员等

简介号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：常规吉非替尼对比治疗常用可切除的EGFR基因的N1-N2期NSCLC-随机III期药理学检验的就此总体肉食动物分析方法。

回顾：肺胰脏—非小蛋白全局-周围/小蛋白/其他胸部

原作者：广东省民主自由的医院吴一龙研究者员等

简介号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR基因计移转到非小蛋白肺胰脏病患者前沿乙酰激酶抑制联合或不联合积极前线全局放疗：III期新开表单药理学随机检验（SINDAS）的初期结果（NCT02893332）。

回顾：肺胰脏-非小蛋白移转到

原作者：四川省民主自由的医院曾铭研究者员等

简介：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对就其死亡-1（PD-1）的人源化IgG4单克隆抗体联合阿昔替尼常用前列腺癌黏膜癌症病患者的Ib期研究者的总肉食动物期和海洋生物标志物分析方法。

回顾：癌症/皮肤胰脏

原作者：北京大学的医院郭军、盛锡楠研究者员等

简介：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的相容性和结果：通用CAR-T蛋白首次化学物质检验疗程病情恶化/难治性T蛋白急性淋巴蛋白胃癌（r/r T-ALL）的相容性和。全体不会议：开发里面的疗程电子技术-免疫疗程。原作者：王岂料等简介：3013宣传片：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利单抗在更早膀胱表皮蛋白胰脏病患者里面的应用领域：一项随机的新开表单II期检验（ORIENT-2）。全体不会议：腹腔肠道胰脏-腹腔膀胱胰脏、肾上腺胰脏和实无道胰脏原作者：徐建明研究者员等简介：4511宣传片：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D特异性CAR-T蛋白对髓母蛋白瘤的根除性疗程全体不会议：里面枢神经系统原作者：代红久、孙斌、杨东、徐晖、朱晶晶、魏佳、赵旭东简介：2522宣传片。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在更早错配修复缺陷病患者里面的应用领域全体不会议：开发里面的疗程学-免疫疗程原作者：沈琳研究者员等简介：3021宣传片。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 诱导CD7-CART疗程病情恶化/难治性ACUTE淋巴蛋白胃癌/淋巴瘤的首创化学物质药理学检验全体不会议: 开发性疗程学-免疫疗程原作者简介：张明志，杨林等简介：3026宣传片: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 西米替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度胺（T）联合应用领域更早实体瘤病患者的Ib期研究者全体不会议：发展性疗程学--底物抑制药物和微海洋生物学原作者：龚继芳，沈琳研究者员等简介：3523宣传片：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin联合紫杉醇和nedaplatin疗程病情恶化性或前列腺癌膀胱表皮蛋白胰脏（ESCC）病患者的II期研究者。全体不会议：腹腔肠道胰脏-腹腔膀胱、肾上腺和实无道胰脏的研究者原作者：王志强，李玉红，王德申，王凤华，任超，谭琼 王志强、李玉红、王德深、王凤华、任超、谭琼简介：4522宣传片：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.全体不会议：腹腔肠道胰脏-腹腔膀胱胰脏、肾上腺胰脏和实无管胰脏的一线疗程原作者：宋艳等简介：4524宣传片：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种分泌物外体网状RNA分类器常用初始活检时检查高等级胰脏的分泌物外体网状RNA分类器：一项多里面心的回顾性研究者全体不会议：循环系统生殖胰脏症---胰脏、睾丸胰脏和胰脏原作者简介：Liaoyuan Li等简介：5522宣传片。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 全局更早宫颈胰脏并发治疗后的常规治疗全体不会议: 妇产科胰脏症原作者简介： 李珉珉等简介：6031宣传片：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼疗程肝脏髓性胰脏的相关性：基于ALTER01031检验的分析方法。不会话：头颈部原作者：长春市的医院用心研究者员简介：6526宣传片。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、大小和年龄对安洛替尼疗程后病患者结局的直接影响: ALTER01031的亚组分析方法全体不会议：头颈部原作者：长春市的医院用心研究者员简介：6527宣传片。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA分析方法预报I-IIIA期非小蛋白肺胰脏（NSCLC）病患者术后病情恶化: GASTO1035和GASTO1018的结果全体不会议：肺胰脏-非小蛋白全局-周围性/小蛋白/小蛋白/其他胸科胰脏症原作者：Si-Yu Wang等简介：9023宣传片：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小蛋白肺胰脏（NSCLC）里面EGFR乙酰激酶抑制的另行型致病机制全体不会议:肺胰脏-非小蛋白前列腺癌肺胰脏原作者简介：赵昕，金结缘，满宇，欧秋香，凯氏，薛武，杨少，范敏 赵昕、金结缘、满宇、欧秋香、凯氏、薛武、杨绍、范敏简介：9528宣传片：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1检验里面更早癌症总肉食动物的替代终点全体不会议：癌症/皮肤胰脏原作者：聂润聪，袁书强，李元芳，陈英波，周志伟 聂润聪、袁书强、李元芳、陈英波、周志伟简介：10030宣传片：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼疗程病情恶化或前列腺癌原发性恶性头骨病患者的II期研究者全体不会议： 性疾病原作者：唐丽娜，牛晓辉，王震，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、朱高煦、蔡启庆、涂崇奇、范正福、杨瑶简介：11525宣传片。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 初步赞誉安罗替尼在更早性疾病病患者多线疗程里面的相容性和。全体不会议：性疾病原作者：姚伟涛，王家强，张鹏，王欣，杜另行辉，田志浩，牛晓颖 姚伟涛、王家强、张鹏、王鑫、杜鑫辉、田志超、牛晓英简介：11526宣传片：414